Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$0.05 CAD
Change Today +0.005 / 11.11%
Volume 35.0K
KNE On Other Exchanges
Symbol
Exchange
OTC US
Berlin
As of 2:31 PM 04/1/15 All times are local (Market data is delayed by at least 15 minutes).

kane biotech inc (KNE) Snapshot

Open
C$0.05
Previous Close
C$0.05
Day High
C$0.05
Day Low
C$0.05
52 Week High
05/30/14 - C$0.12
52 Week Low
11/24/14 - C$0.03
Market Cap
5.4M
Average Volume 10 Days
312.6K
EPS TTM
C$-0.01
Shares Outstanding
107.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KANE BIOTECH INC (KNE)

Related News

No related news articles were found.

kane biotech inc (KNE) Related Businessweek News

No Related Businessweek News Found

kane biotech inc (KNE) Details

Kane Biotech Inc., a biotechnology company, is engaged in the development and commercialization of products to prevent and remove biofilms. Its products include DispersinB, an antibiofilm enzyme for the wound care market; Aledex for the medical device coating market; KBI antibacterial disinfectant; and StrixNB for the oral care market. The company was founded in 2001 and is based in Winnipeg, Canada.

Founded in 2001

kane biotech inc (KNE) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: C$195.0K
Chief Financial Officer
Total Annual Compensation: --
Compensation as of Fiscal Year 2013.

kane biotech inc (KNE) Key Developments

Kane Biotech Inc. Summarizes Compelling Oral Care Study Results

Kane Biotech Inc. provided a summary of the efficacy and safety study results on its companion animal oral care water additive. The studies were conducted by independent third party research organizations. The dog efficacy study was a controlled, randomized, masked study with 30 dogs each per control and treatment groups. Both groups were fed normal diets, but the treatment group received drinking water containing Kane's oral care water additive at the recommended dosage, while control group received normal water for consumption throughout the study period. On Day 0, dental prophylaxis was performed for each dog and calculus score was confirmed as a score of (0).Then calculus was measured on day 28, 56, 84 of the study period using modified Warrick-Gorrel method. The mean calculus scores for the company's oral care water additive were better than the control throughout the study. On day 28, 56, and 84 the calculus score for the water additive was 14.2%, 23.5%, and 25.4% lower than the control group, respectively. The difference in calculus scores between the control and treatment group was statistically significant. In addition, no significant differences were observed between the two treatment groups for either animal body weights or food consumption. 25.4% reduction in calculus (p<0.0229). No change in body weight or food consumption. The water additive is an effective first step in pet oral care. The dog safety study was a randomized, masked laboratory study with three parallel treatment groups each contained 6 dogs. The product was administered as added to their drinking water at 0, 1 and 5 times the recommended application volume. Dogs were treated for a total of 30 consecutive days. Variables measured included clinical observations, physical examinations, oral assessments, body weights, and clinical pathology that include a comprehensive list of hematology and serum chemistry indices, and coagulation profile measured at regular time points during study period. With the exception of soft feces (noted intermittently for 3 of 6 dogs in the 5 times use rate group) findings documented during clinical observations, physical examinations and oral assessments were within normal limits. Trends were similar across treatment and control groups. Evaluation of clinical pathology indices revealed no group trends or individual effects which were considered treatment-related. In conclusion, the safety study successfully demonstrated the product is safe up to 5 times the recommended usage rate during the study period. Passed comprehensive safety assessment up to 5 times usage rate. Contains ingredients that meet Health Canada's LRVHP (Low Risk Veterinary Health Program).

Kane Biotech Introduces bluestem™

Kane Biotech Inc. announced that it will be introducing the company’s bluestem pet oral care brand in the over the counter (OTC) retail market. bluestem™ is a specifically formulated oral care product that contains the company’s patent pending coactiv+™ technology. The initial product introduction will be a water additive for daily use in four flavours including original, vanilla mint, chicken and salmon, with additional product formulations to follow. bluestem is now available at select pet stores in Manitoba.

Kane Biotech Appoints Mark Nawacki to the Board of Directors

Kane Biotech Inc. announced the appointment of Mark Nawacki to its board of directors. Mark will be replacing Richard Cherney who is retiring from the board. Mr. Nawacki served as Executive Vice President, Business and Corporate Development of Paladin until September 2014. Mark joined Paladin in 2003 and was responsible for all business, corporate and product development activities.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KNE:CN C$0.05 CAD +0.005

KNE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KNE.
View Industry Companies
 

Industry Analysis

KNE

Industry Average

Valuation KNE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 18.2x
Price/Book 5.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 20.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KANE BIOTECH INC, please visit www.kanebiotech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.